Active ingredientAtrasentanCat. No. P-A214-001CAS 173937-91-2Family · Pharmaceutical analytical standards
Atrasentan
A selective endothelin A receptor antagonist, approved in the United States in April 2025 to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression. This family brings together the active ingredient and labelled standards.
Did you know?Before reaching the kidneys it was studied for years against prostate cancer: its official name was recorded by the WHO in 2001, a full 24 years before approval.
Go to the active ingredient →Active ingredientAtrasentanCat. No. P-A214-001CAS 173937-91-2
Isotopically labelledAtrasentan-d18Cat. No. P-A214-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.